Human multiple myeloma (MM) represents a highly aneuploid tumor as shown by cytogenetic studies. This may partly explain the heterogeneity with regard to growth factor requirements demonstrated among MM cells. We have previously reported the expression of insulin-like growth factor I (IGF-I) and IGF-l receptor (IGF-IR) mRNA in some MM cell lines. In this study we investigated the role of IGF-l as a growth andlor survival factor in three MM cell lines: LP-1, EJM, and Karpas 707. We report that all cell lines expressed IGF-I and IGF-IR mRNA and protein. LP-l and Karpas EVERAL CYTOKINES have been suggested to stimulate the growth of human multiple myeloma (MM) biopsy cells and cell lines.' Interleukin (1L)-6 seems to be the major growth factor both in vitro and in but other cytokines using gp 130 as a signal transducer chain, such as ciliary neurotrophic factor (CNTF), IL-11, leukemia inhibitory factor (LIF), and oncostatin M (OSM), have been reported to stimulate the proliferation of some MM cell lines.6 The role of the latter cytokines in vivo has not as yet been established. Interferon (1FN)-a at relatively low concentrations may act as a growth factor for MM biopsy cells7 and in MM cell lines, by inducing autocrine IL-6 production in vitro.8 At higher concentrations, however, IFN-a inhibits growth of MM cell lines and biopsy cells and may even be c y t o t o~i c .~~'~'~ In studies of freshly explanted MM cells with varying contamination of nonmalignant bone marrow cells, and in some cell lines, IL-10, granulocyte colony stimulating factor (G-CSF), tumor necrosis factor (TNF)-a, IL-10, IL-3, IL-5, and granulocyte-macrophage (GM)-CSF have been reported to stimulate proliferation.'.' '-l4 The mechanisms of action of these cytokines are not clear but may be direct (IL-10) or indirect, either by stimulating bone marrow stromal cells to IL-6 production (G-CSF, GM-CSF, TNF-a, IL-10, IL-5) or by the upregulation of IL-6 receptors on MM cells (IL-3).'' Insulin-like growth factor I (IGF-I) has emerged in recent years as a factor playing key roles in the malignant transformation of murine fibroblasts.I6 IGF-I has also been implicated as a survival factor because it prevents c-myc-induced apoptosis in rat fibr0b1asts.l~ In addition, a constitutive expression of IGF-I receptor (IGF-IR) was recently demonstrated to rescue murine fibroblasts from etoposide-induced apoptosis." In this study we investigate the role of IGF-I in the regulation of growth and survival in three IL-6-independent MM cell lines. We demonstrate that all cell lines expressed IGF-IR and IGF-I both at the mRNA and protein levels. Two of the cell lines were stimulated to proliferation by exogenous IGF-I. The IGF-I-stimulated and the spontaneous growth of these cell lines was inhibited by an IGF-IR blocking antibody. The results thus demonstrate that IGF-I acts as a paracrine growth factor for some MM cell lines, and also suggest that an autocrine IGF-I loop may participate in maintaining growth and survival of MM cell lines.
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Human B lymphocytes and B-lymphocytic tumors variably express IGF-IR. 19-2' In vivo studies have shown that IGF-I has profound effects on lymphoid tissues by increasing CD4' T cell and B cell populations, resulting in enhanced immunoglobulin s y n t h e s i~.~* <~~ In vitro, IGF-I regulates Bcell development, eg, by potentiating the expansion of IL-7-dependent pro-B ~e l l s .~~,~~ Epstein-Barr virus carrying Blymphoblastoid cells, normal plasma cells, and some MM cells express IGF-IR; some of these cells have been shown to respond by increased DNA synthesis on IGF-I stimulation, but no induction of cell division has been d e m o n~t r a b l e .~~~~~
In this study we investigate the role of IGF-I in the regulation of growth and survival in three IL-6-independent MM cell lines. We demonstrate that all cell lines expressed IGF-IR and IGF-I both at the mRNA and protein levels. Two of the cell lines were stimulated to proliferation by exogenous IGF-I. The IGF-I-stimulated and the spontaneous growth of these cell lines was inhibited by an IGF-IR blocking antibody. The results thus demonstrate that IGF-I acts as a paracrine growth factor for some MM cell lines, and also suggest that an autocrine IGF-I loop may participate in maintaining growth and survival of MM cell lines.
IGF-I STIMULATES GROWTH IN MULTIPLE MYELOMA 2251
set up as described for LP-l. Both cells growing in suspension and adherent cells were counted at harvest.
In the receptor blocking experiments. an IGF-IR antibody ((uIR3) was used (Oncogene Science. Uniondale, NY). In parallel experiments with the Karpas 707 cell line, we also used an anti-IGF-I antibody (Oncogene Science). An isotypic antibody against TSH was used as a negative control (Pharmacia). The cells were seeded as described above in 0 8 , O.S%, or 1 0 % FBS. The cells were preincubated with the antibodies for 30 minutes before the addition of IGF-I. Antibodies were also added after 48 hours and 96 hours of culture. At 120 hours of incubation, the cells were harvested and counted as described above. In parallel experiments. DNA synthesis was determined. The cells were incubated with I pCi of 'H-TdR (specific activity 25 Cilmmol: Amersham, Buckinghamshire, UK) for the last 24 hours of incubation. The cells were harvested by a cell harvester (Scatron, Lierbyen. Norway) and the incorporated radioactivity was determined by a liquid scintillation counter (Beckman, Irvine. CA).
RT-PCR. Exponentially growing cells from stock cultures were harvested. and RNA was prepared using the guanidinium isothiocyanatelCsCI method." One microgram was used to prepare cDNA. cDNA synthesis was primed with oligo d(T) as described elsehere.'^ One tenth of the cDNA from 1 pg RNA was used in each PCR. Thirty cycles of amplification were performed. The ubiquitously expressed G3PDH gene was used as a control for the quality of the cDNA. Primers for IGF-I and its receptor were purchased from Clontech Laboratories (Palo Alto, CA). IGF-I primers: S'ACA TCT CCC ATC TCT CTG GAT TTC CTT TTG C3'. 3' primer:
IR primers: S'primer: S'GAA TGG ACT GCT GTA TGC CTC TGT GAA CC3'. 3'primer: GTG AAA TCT TCG GCT ACC ATG CAA I T C CG3'. As negative controls we included tubes without cDNA. IGF-I or IGF-IR cDNA were included as positive controls (Clontech). The S' primers and the 3' primers were from different exons to avoid genomic contamination. The specificity of the product was confirmed by its size and by cutting the products with restriction enzymes (Avo 11, Est XI for IGF-I and Hindlll, Sau-?nl for IGF-IR). The products were run on a l % agarose gel with a size marker (Clontech). The resulting pattern of restriction fragments was compared with the expected one extracted from GenBank.
Radioimmrtnons.say (RIA).for IGF-I. Cells at a concentration of 2 X 10' cellslmL were incubated with or without FBS in 24 well plates (0.5 mLlwell). After 96 hours the conditioned medium was collected. The medium was centrifuged and treated with standard acid-ethanol, as described by Daughaday et al." Briefly, 0.1 mL FBS was mixed with 0.9 mL acid-ethanol (125% 2 mollL HCI and 875% ethanol. vol/vol), and incubated at room temperature for 30 minutes. The acid-ethanol mixture was then centrifuged in a microcentrifuge for 30 minutes at 4°C. The RIA was performed using recombinant human IGF-I as a tracer and standard, and rabbit polyclonal anti-FBS as described." The lower detection limit of the assay was 20 ng/mL. In FRS supplemented medium alone, the level of IGF-I was below the detection limit (<20 ng/mL).
N O W cytomet? cr.s.say. Cells growing exponentially in RPM1 1640 with 10%-FBS were used. Cells were incubated in RPM1 1 6 4 0 , pH 3, for I minute to remove bound ligand, washed in PBS and incubated for 30 minutes with primary antibody ((rIR.3) or an irrelevant isotypic antibody (aTSH). As a positive control we used an antibody specific for MHCl (HLA-I clone W6/32, Dakopatts AB, Receptor binding studies. The cells were incubated in RPMI 1640. pH 3, for I minute to remove bound ligand, washed, and then kept in medium without FBS. "'I-IGF-I (2.000 Cilmmol; Amersham, UK) was added. 10,000 cpm/well. Cold IGF-I in increasing concentrations (0 to 1 0 0 nmol/L), insulin ( 1 0 0 nmol/L), or IGF-I1 ( 1 0 0 nmol/L), was added to compete for binding. The cells were then incubated on ice for 3 hours. The cells growing in suspension (LP-I ) were centrifuged and washed twice with cold RPMI 1640, the supernatant was discarded. and the bound radioactivity was measured in a y-counter (LKB Wallac, Pharmacia. Finland). The adherent cells (EIM, Karpas 707) were washed twice and then incubated for IS minutes at room temperature in a lysis buffer ( 1 0 0 mL PBS, I mL Triton X-100, 10 mL glycerol, 20 mmol/L HEPES, pH 7.3). The solution was then transferred to tubes and the bound radioactivity was measured. The specific binding refers to total binding (cpm) -binding in the presence of 1 0 0 nmol/L cold IGF-I (cpm).
Statistical ana/y.sis. Data from the growth assays were analyzed using Student's r-test for unpaired samples.
RESULTS

Expression ef IGF-IR on MM cell lines.
Little is known about the expression of IGF-IR on normal plasma cells or their malignant counterparts, MM cells. To study the expression of IGF-IR mRNA, we isolated RNA from exponentially growing cells from the MM cell lines LP-l , EJM, and Karpas 707 and performed RT-PCR. As shown in Fig 1, all cell lines expressed IGF-IR mRNA. The specificity of the fragments was confirmed by cutting the fragments with restriction enzymes (Hind111 and SuuJal). G3PDH was used as a control for the quality of the cDNA (data not shown).
The expression of surface IGF-IR was analyzed using two methods: flow cytometry and a receptor binding assay. The cells were first incubated in acid medium (pH 3) to prevent interference from IGF-I produced by the cells or present in the FBS. The results from the flow cytometry analysis show that the LP-l cell line expresses the largest number of IGF-IR. IGF-IR expression at lower levels was found on EJM and Karpas 707 cells (Fig 2) . In the assay, anti-TSH was used as a negative control and anti-MHC as a positive control. The fluorescence in the negative control is mainly a result of autofluorescence as can be seen when no FITC-conjugated fragment is added (data not shown). To quantify the number of receptors on these cell lines, we performed receptor binding studies using '2sI-IGF-I and increasing concentrations of cold IGF-I (Fig 3) . Wells with cold insulin or IGF-I1 were 
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included to verify that binding is attributed to IGF-IR and not to insulin or IGF-I1 receptors. The affinity of the ligands for the IGF-IR is, in descending order: IGF-I, IGF-11, insulin, which is consistent with our results. In the binding studies the specific binding (total binding -binding in the presence of 100 nmoVL cold IGF-l) of I2'I-IGF-I to the LP-l cell line was 600 cpd0.6 X IO6 cells, while the specific binding to EJM and Karpas 707 was 390 cpd0.6 X lo6 cells and 430 cpd0.6 X 10" cells, respectively (Fig 3) . In comparison, a B-lymphoma cell line (U-698) turned out to have very low levels of I2'I-IGF-I binding (90 cpd0.6 X IO6 cells; data not shown) which is consistent with published data.27
Expression of IGF-I. We have previously found IGF-I mRNA expression in some lines of our panel of MM cell lines. 37 We therefore isolated RNA from exponentially growing LP-l, EJM, and Karpas 707 cells and performed RT-PCR. The specificity of the reaction was ensured by the use of primers from different exons (genomic contamination would yield a larger fragment) and by cutting the fragments with restriction enzymes (Ava 11, Bsr XI). The pattern of fragments was compared with the expected pattern extracted from GenBankR. The results show that all three lines expressed IGF-I mRNA (Fig 4) .
We also measured IGF-I in media from exponentially growing cells from the LP-1, EJM, and Karpas 707 cell lines. The cells were incubated with or without FBS for 96 hours and the medium was harvested. The binding proteins were extracted in acid ethanol and an RIA for IGF-I was performed. Low levels of IGF-I (20 to 25 ng/mL) were found in conditioned media from all three cell lines incubated with FBS. No IGF-I was detected in medium harvested from the cells incubated without FBS or in Fl3S supplemented rnedium alone (Table 1 I with or without FBS (Fig S ) . The cells were seeded at a concentration of 0.2 X 10' cells/mL and cultured for 120 hours. The number of viable cells was then counted in a hemocytometer using the trypan blue exclusion test. DNA synthesis was measured in parallel experiments by incubating the cells with 'H-TdR for the last 24 hours of culture (Table 2) . LP-l (Fig SA) cells were stimulated to proliferation in a dose-dependent manner by IGF-I both without and in the presence of 05% and IO% FBS. The stimulatory effect was moderate (up to SO%) in the two concentrations of FBS. EJM (Fig SB) did not respond to IGF-I in this assay. The Karpas 707 cell line (Fig SC) was also growth stimulated by IGF-I both without and in the presence of O S % and 10% FBS. The effect is similar to that observed in the LP-l cultures (up to 45% growth stimulation). IGF-I could also stimulate 'H-TdR incorporation in the LP-l and Karpas 707 cell lines but had no effect on the EJM cell line ( Table 2 ). The stimulatory effect was similar to that seen when the cells were counted (up to 50%).
The efect of an IGF-IR blocking antibody (aIR3) on the growth of M M cells. The finding that the cell lines in this study simultaneously expressed IGF-I and IGF-IR prompted us to investigate the role of IGF-I as a possible autocrine growth and survival factor for MM cells. Cells from the three MM cell lines LP-l (Fig 6A) , EJM (Fig 6B) , Karpas 707 ( Fig 6C) were cultured without, with O S % or 10% FBS, and in increasing concentrations of IGF-IR blocking antibodies (aIR3). For the Karpas 707 cell line, an anti-IGF-I antibody was also used in similar experiments. After 120 hours the viable cells were counted using the trypan blue exclusion test. An anti-TSH antibody was used as a negative control. We also examined whether the antibody could inhibit the effect of exogenous IGF-I (100 nmolk). The spontaneous growth of LP-l cells (Fig 6A) was inhibited up to 40% by the antibody in a dose-dependent manner. The antibody could also inhibit IGF-I (100 nmol/L) stimulated growth as depicted. The growth inhibitory effect of the anti-IGF-IR antibody was more pronounced in 0 3 % FRS. The most notable response, however, was seen in the Karpas 707 cell line. When maintained in O S % FBS, the Karpas 707 cells did not grow but survived for 120 hours (Fig 6C) . With the addition of S & n L blocking antibody, only SO% of the cells were viable after 120 hours. As in LP-l cells, the antibody also inhibited IGF-l-stimulated growth. In the presence of 10%-FBS and S &mL anti-IGF-IR antibody, the growth of Karpas 707 cells was completely abrogated, and after 120 hours of incubation the number of viable cells had decreased by IO% to 15%. The antibody had no effect on the growth of EJM (Fig 6B) . We tested concentrations up to 10 &mL without any growth inhibitory effect on EJM cells (data not shown). The inhibitory effect of the anti-IGF-I antibody on the growth of the Karpas 707 cells was dose-dependent and similar to the effect seen with the anti-IGF-IR antibodies ( Table 2) .
DISCUSSION
Cytogenetic studies have shown that human MM is a highly aneuploid tumor,3x.3' which may explain the extensive biological heterogeneity with regard to growth factor requirements demonstrated among biopsy cells and MM cell lines in vitro during the last decade. IL-6 seems to be the most important growth factor even though several MM cell lines have been demonstrated to be unresponsive to IL-6.'4 In a few cases, MM cell lines were reported to respond by proliferation to other cytokines also using gp 130 as a transducer chain, ie, IL-I I , CNTF, LIF, and OSM. 6 In freshly explanted MM cells, with varying contamination of nonmalignant bone marrow cells, and in some MM cell lines, several cytokines have been reported to stimulate proliferation, eg, IL-IO, G-CSF, TNF-a, IL-ID, IL-3, IL-S, and GM-CSF.'.""' Although IGF-I is a well characterized growth and survival factor for several mouse and human nonhematopoietic cell few studies have focused on the possible func- 
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To make comparisons possible, the results are expressed as percentage of control (treated group -untreated groupbntreated group) x 100). The figures are calculated from means of one representative experiment.
Abbreviations: NS, not significant; ND, not determined.
able heterogeneity among MM cell lines, in that LP-I cells express more receptors than do the EJM and Karpas 707 cell lines. This variability in expression of IGF-IR is expected in view of the long history of evolution of MM clones both in vivo and in vitro, which allows for the development of considerable genetic variability and, as a consequence, a plethora of phenotypic properties. During this continuous evolution of the MM clones, selection on the basis of developed phenotypic characteristics will occur in a Darwinistic manner. MM cells with better adaptation to the environment will be gradually selected, and the dominating cells within the tumor at a given time point will have an improved capacity for growth and survival as compared with MM cells at an earlier stage of the tumor progression. Several genes, including IL-6, c-myc, bcl-2, Rb, p53, ras," and, as demonstrated in this paper, IGF-I, seem to be involved in the progression of MM cells toward faster growth, increased survival, and a higher degree of independence of host control mechanisms.
To study the production of IGF-I in MM cell lines, we performed PCR and RIA. All cell lines expressed IGF-I mRNA both when cultured in the absence (data not shown) and in the presence of serum. Since the PCR was not quantitative, no conclusions can be drawn about the levels of transcription. When cultured in the presence of FBS, IGF-I protein was detected in supernatant from all three cell lines by RIA. However, when cells were cultured without FBS, no IGF-I protein could be detected in the supernatants. Consistent with these findings, Kimata et a129 reported that IGF-I was not expressed in normal spleen plasma cells nor in established MM cell lines when cultured without serum.
When the effect of exogenous IGF-I on the growth of the MM cell lines was analyzed, we found that LP-l and Karpas 707 cells were stimulated to proliferation both in the absence and in the presence of 0.5% and 10% FBS, whereas IGF-I had no effect on the growth of EJM cells. These differences For personal use only. on September 24, 2017. by guest www.bloodjournal.org From in response to exogenous IGF-I cannot easily be correlated to the number of IGF-IR or the endogenous IGF-I production. In a gastric carcinoma cell line, the lack of growth stimulatory effect of IGF-I was recently suggested to be due to the inhibitory effect of IGF-I-binding proteins!' Further studies will reveal whether IGF-I-binding proteins may act as inhibitors of mitogenic signaling via IGF-I, also in MM cell lines. The results from the 'H-TdR incorporation analysis showed that IGF-I stimulates DNA synthesis in a way that matches the increased cell number. Thus the addition of IGF-I seems to alter the growth fraction marginally. This finding indicates that IGF-I is a weak mitogen and that the effect of IGF-I on growth of MM cells is mainly caused by increased cell survival. Consistent with this idea, preliminary data show that IGF-I can inhibit apoptosis in some MM cell lines and furthermore that anti-IGF-IR antibodies can induce apoptosis as determined by TdT-mediated dUTP-biotin nick end labeling (TUNEL).
The finding that all cell lines simultaneously express both IGF-I receptors and IGF-I points to a possible autocrine stimulation of proliferation by IGF-I in MM cells. IGF-IR blocking antibodies have been shown to inhibit the growth in vitro of certain human tumor cell lines,"3s44 but the effect on MM cell lines has not previously been studied. The IGF-I-stimulated growth of LP-1 and Karpas 707 cells was blocked by the antibody. The IGF-IR antibody also inhibited the spontaneous growth of LP-l and Karpas 707 cells, while no effect was observed in the EIM cells. The growth inhibitory effect of the IGF-IR antibody was seen both in the absence and in the presence of 0.5% and 10% FBS. In the Karpas 707 cell line the antibody not only inhibited growth completely, but also induced cell death. The effect of an anti-IGF-I antibody on the growth of the Karpas 707 cells was similar to the effect seen with anti-IGF-IR antibodies. When the cells were grown in the absence of serum, no IGF-I protein was detected in the culture supernatants. However, the anti-IGF-I antibodies could still inhibit growth under these conditions. This suggests that IGF-I levels below the detection limit can still be biologically active. This interpretation is consistent with the fact that IGF-I mRNA is expressed in cells after serum starvation (data not shown). Taken together, these facts strongly support the idea that IGF-I acts as an autocrine growth and survival factor, at least for LP-l and Karpas 707 cells. The reason for the relative inefficiency of the anti-IGF-IR antibody in the LP-1 cells may simply reflect that these cells express a higher density of receptors than the Karpas 707 cells and thus the effect of IGF-I can only partially be blocked.
We can thus conclude that IGF-I can function as a growth factor for some MM cell lines, that it seems also to be a survival factor for MM cell lines, and that it may act both in a paracine and autocrine fashion.
We have previously shown that during the in vitro progression of the U-266 cell line, it has become independent of exogenous IL-6 by acquiring an autocrine production of IL- 6 ! 5 Although autocrine IL-6 may contribute to the growth of MM cell lines in vitro, the importance of autocrine E -6 production in vivo is unclear.' Whether the IL-6 scenario is relevant also for IGF-I has yet to be determined, but it may well be that IGF-I can act similar to IL-6 in switching from a paracrine to an autocrine growth factor during the progression of MM. Finally, MM clones may evolve to complete independence of IGF-I as shown in this study by the EJM cell line. Also with respect to the dual function as a factor stimulating both growth and survival, IGF-I seems to have similarities with K-6. As MM cells grow exclusively in the bone marrow in close contact with bone trabeculae, it is interesting to note that IGF-I is produced by some bone cells, eg, osteoblasts,46 and may stimulate other cells to cytokine production, eg, IL-6. The osteoblast itself is interesting in this regard as it may thus produce both IL-6 and IGF-l, cytokines stimulating MM cells. MM cells thus seem to have interacted by essentially unknown mechanisms, with several cell types in the bone marrow, during the Darwinian evolution discussed above. Along with IL-6, IGF-I appears to be one of the important ligands stimulating survival and growth.
The net growth of tumors is regulated by the rate of proliferation and the rate of cell death. This is illustrated in the c-myc driven mouse plasmacytomas, where IL-6 provides a necessary survival signal preventing the apoptotic effect of the myc protein and thus promoting gr~wth.~' In human MM, c-myc translocations are very rare but the MM cells often display high levels of c-myc mRNA and implicating a functional deregulation of the myc gene also in human MM. The recent finding that a deregulated c-myc gene induces apoptosis in growth factor deprived murine fibroblasts and some hematopoietic cells'735' further stresses the need for survival factors for maintenance of growth. Some MM cell lines are dependent on L -6 for survival but many are It therefore seems possible that other survival mechanisms may be operating in E-6 independent MM cells. The expression of bcl-2 is high in MM but its role in MM is unclear since normal plasma cells also express high levels of bcZ-2." Although IGF-I is a rather weak mitogen, it is a potent survival factor that has been demonstrated to inhibit c-myc-induced apoptosis." Neither IL-6 nor IGF-I have been shown to regulate the levels of b~l-2,".'~ suggesting actions through separate pathways. In a recent report, IL-6 was shown to promote survival by upregulating bclx L .~~ The mechanism by which IGF-I mediates survival is not known.
In vivo, MM is characterized by long-lived cells with a low proliferative activity. Our findings provide evidence for novel mechanisms, the paracrine and autocrine stimulation by IGF-I, by which the MM cells may ensure survival and growth. Further studies will clarify the relationship of IGF-I to other growth and survival factors of possible importance in the pathogenesis of MM, eg, IL-6 and genes of the bcl-2 family.
